Search

Ertugliflozin

[A261951, L1132] It was also approved by the European Commission in March 2018.[L48621] … It works to block glucose reabsorption from the glomerulus.[A31581] Ertugliflozin was first approved by the FDA in December 2017.

Somatostatin

It is secreted by the D cells of the islets to inhibit the release of insulin and glucagon, and is also generated in the hypothalamus, where it inhibits the release of growth hormone and thyroid-stimulating … Prosomastatin is further process into two active forms, somatostatin-14 (SST-14) and somatostatin-28 (SST-28), an extended SST-14 sequence to the N-terminus [A20384].

Dextropropoxyphene

Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. … Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States.

Ferrous gluconate

Desipramine

They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. … The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission.

Carbinoxamine

Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. … The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse, as many

Melatonin

In mammals, melatonin is produced by the pineal gland. … Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers.

Polatuzumab vedotin

Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. … [L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was approved by Health Canada on July 9, 2020.[L44141]

Cefaclor

Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.

Nalmefene

[L40684] It acts as an antagonist at the mu (μ)-opioid and delta (δ)-opioid receptors and a partial agonist at the kappa (κ)-opioid receptor. … [L1024] Nalmefene was approved in the United States in 1995 as an antidote for opioid overdose.[A245839] Nalmefene injection is used to manage known or suspected opioid overdose.